Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

Neoadjuvant FOLFIRINOX and gemcitabine/nab-paclitaxel (GemNP) therapies are increasingly used to treat patients with pancreatic ductal adenocarcinoma (PDAC). However, limited data are available on their clinicopathologic prognosticators. We examined the clinicopathologic factors and survival of 213...

Full description

Bibliographic Details
Main Authors: Yi Tat Tong, Zongshan Lai, Matthew H. G. Katz, Laura R Prakash, Hua Wang, Deyali Chatterjee, Michael Kim, Ching-Wei D. Tzeng, Jeffrey E. Lee, Naruhiko Ikoma, Asif Rashid, Robert A. Wolff, Dan Zhao, Eugene J. Koay, Anirban Maitra, Huamin Wang
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cancers
Subjects:
pancreatic cancer
neoadjuvant therapy
FOLFIRINOX
gemcitabine/nab-paclitaxel
tumor response grade
tumor stage
Online Access:https://www.mdpi.com/2072-6694/15/9/2608

Internet

https://www.mdpi.com/2072-6694/15/9/2608

Similar Items